Jinmin Miao, Jiajun Dong, Yiming Miao, Yunpeng Bai, Zihan Qu, Brenson A. Jassim, Bo Huang, Quyen Nguyen, Yuan Ma, Allison A. Murray, Jinyue Li, Philip S. Low and Zhong-Yin Zhang

Chem. Sci., 2023, 14, 12606
DOI: 10.1039/D3SC04541B

Chemistries of bifunctional PROTAC degraders

Chaoguo Cao, Ming He, Liguo Wang, Yuna He and Yu Rao

Chem. Soc. Rev., 2022, 51, 7066
DOI: 10.1039/D2CS00220E

Covalent PROTAC design method based on a sulfonyl pyridone probe

Qinhong Luo, Yaqi Wang, Zhanfeng Hou, Huiting Liang, Licheng Tu, Yun Xing, Chuan Wan, Jianbo Liu, Rui Wang, Lizhi Zhu, Wei Han, Jianlong Wu, Fei Lu, Feng Yin and Zigang Li

Chem. Commun., 2024, 60, 686
DOI: 10.1039/D3CC05127G

Targeted protein degradation: advances in drug discovery and clinical practice

Guangcai Zhong, Xiaoyu Chang, Weilin Xie and Xiangxiang Zhou

Sig Transduct Target Ther, 2024, 9
DOI: 10.1038/s41392-024-02004-x

VIPER-TACs leverage viral E3 ligases for disease-specific targeted protein degradation

Kyle Mangano, Robert G. Guenette, Spencer Hill, Shiqian Li, Jeffrey J. Liu, Cory M. Nadel, Suresh Archunan, Arghya Sadhukhan, Rajiv Kapoor, Seung Wook Yang, Kate S. Ashton and Patrick Ryan Potts

Cell Chemical Biology, 2025, 32, 423
DOI: 10.1016/j.chembiol.2025.02.002

Ginsenoside Rh2- functionalized liposomes enhanced BRD4-PROTAC delivery and antitumor efficacy via improved tumor targeting and ECM remodeling

Lijuan Wen, Jialei Rao, Jiaoting Chen, Fang Li, Xixi Chen, Shenpeng Guo, Binghui Cui, Caisheng Qiu and Weiliang Chen

Materials Today Bio, 2026, 36, 102767
DOI: 10.1016/j.mtbio.2026.102767

Development and Mechanistic Evaluation of Cathepsin B‐Activatable Peptide‐Drug Conjugate PROTACs for Targeted Protein Degradation in Malignant Tumors: Advancing Precision Protein Degradation Therapeutics in Oncology

Qingqing Zhang, Yu Liu, Jie Zhang, Hengtao Dong, Xiaoyan Pan and Jie Zhang

Small, 2026, 22
DOI: 10.1002/smll.202506562

MOF-based nanoparticles for tumor-targeted protein degradation and photodynamic therapy induce enhanced anti-tumor immunity

Huanhuan Zhu, Fei Gao, Yuan Li, Min Jiang, Yue Zhang, Chen Kan, Lin Han, Shaobo Xue, Kesheng Wang, Qiangyuan Fan, Honggang Hu, Fenyong Sun and Zunzhen Ming

Nano Today, 2024, 56, 102308
DOI: 10.1016/j.nantod.2024.102308

PROTACs improve selectivity for targeted proteins

Lihua Liu, Xian Guan, Jiezhen Zhuo, Xifeng Wu and Xin Han

Acta Materia Medica, 2025, 4
DOI: 10.15212/AMM-2025-0015

Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 2023

Esther C. Y. Lee, Kyle D. Reichl and Ariamala Gopalsamy

Expert Opinion on Therapeutic Patents, 2024, 34, 211
DOI: 10.1080/13543776.2024.2355258

Targeted protein degradation technologies: Emerging mechanisms and nano-based innovations

Mingge Hou, Runze Zhao, Shenghui Wang, Bing Jiang and Xiyun Yan

Nano Research, 2025, 18, 94907983
DOI: 10.26599/NR.2025.94907983

Successes and challenges in the development of BD1-selective BET inhibitors: a patent review

Monica Viviano, Alessandra Cipriano, Emanuele Fabbrizi, Alessandra Feoli, Sabrina Castellano, Gianluca Sbardella, Antonello Mai, Ciro Milite and Dante Rotili

Expert Opinion on Therapeutic Patents, 2024, 34, 529
DOI: 10.1080/13543776.2024.2327300

Recent advances in dual PROTACs degrader strategies for disease treatment

Jianyu Liu, Yanzhuo Liu, Jiao Tang, Qianyuan Gong, Guoyi Yan, Hengrui Fan, Xueping Zhang and Chunlan Pu

European Journal of Medicinal Chemistry, 2024, 279, 116901
DOI: 10.1016/j.ejmech.2024.116901

The role of TRIM proteins in chronic inflammation-associated musculoskeletal diseases

Gregory Livshits and Alexander Kalinkovich

Ageing Research Reviews, 2025, 111, 102837
DOI: 10.1016/j.arr.2025.102837

Dual-PROTACs based on natural product derivative potassium dehydrographolide succinate: design, synthesis, and antitumor activity of a novel EGFR degrader

Ruling Shi, Peixi Zhang, Ming Chen, Weiming Lu, Meng Xu, Huagong Zeng, Jie He, Yan Wang, Yirong Lin and Jieqing Liu

Med Chem Res, 2025, 34, 1695
DOI: 10.1007/s00044-025-03434-0

Reprogramming of cancer metabolism via photoresponsive nano-PROTAC enhances pyroptosis-mediated immunotherapy

Byeongmin Park, Jiwoong Choi, Jae-Hyeon Lee, Yelee Kim, Woohyeong Lee, Ansoo Lee, In-Cheol Sun, Hong Yeol Yoon, Yongju Kim, Sun Hwa Kim, Yoosoo Yang, Kwangmeyung Kim, Jooho Park and Man Kyu Shim

Sig Transduct Target Ther, 2025, 10
DOI: 10.1038/s41392-025-02405-6

Recent advances in targeted protein degraders as potential therapeutic agents

Na Yang, Bo Kong, Zhaohong Zhu, Fei Huang, Liliang Zhang, Tao Lu, Yadong Chen, Yanmin Zhang and Yulei Jiang

Mol Divers, 2024, 28, 309
DOI: 10.1007/s11030-023-10606-w

Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation

Jinmin Miao and Zhong‐Yin Zhang

ChemMedChem, 2024, 19
DOI: 10.1002/cmdc.202300669

Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice

Tadatoshi Sato, Christian D. Castro Andrade, Sung-Hee Yoon, Yingshe Zhao, William J. Greenlee, Patricia C. Weber, Usha Viswanathan, John Kulp, Daniel J. Brooks, Marie B. Demay, Mary L. Bouxsein, Bruce Mitlak, Beate Lanske and Marc N. Wein

Proc. Natl. Acad. Sci. U.S.A., 2022, 119
DOI: 10.1073/pnas.2214396119

ClpP-based MtPTAC technology enables targeted degradation of inner mitochondrial membrane proteins

Yuxin Yao, Dachi Wang, Haoyu Gong, Ruibin Jiang, Yang Liu, Yijun Liu, Xin Lai, Zhaoyang Xu, Wei Zhou, Haorong Li and Xiaohong Fang

Bioorganic & Medicinal Chemistry, 2025, 130, 118350
DOI: 10.1016/j.bmc.2025.118350

JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis

Junchao Wu, Lisha Li, Quangang Zhu, Tingrui Zhang, Fengze Miao, Zhen Cui, Guoqiang Dong, Zongguang Tai and Zhongjian Chen

Biomedicine & Pharmacotherapy, 2024, 171, 116167
DOI: 10.1016/j.biopha.2024.116167

Advancements in delivery Systems for Proteolysis-Targeting Chimeras (PROTACs): Overcoming challenges and expanding biomedical applications

Yawei Yu, Weitong Hu, Yihua Xu, Hong-bin Xu and Jianqing Gao

Journal of Controlled Release, 2025, 382, 113719
DOI: 10.1016/j.jconrel.2025.113719

Research progress in DNA damage response (DDR)-targeting modulators: From hits to clinical candidates

Binbin Cheng, Zongbao Ding, Yimeng Hong, Yaping Wang, Yingxing Zhou, Jianjun Chen, Xiaopeng Peng and Chunlai Zeng

European Journal of Medicinal Chemistry, 2025, 287, 117347
DOI: 10.1016/j.ejmech.2025.117347

Research progress of PTP1B inhibitors and degraders

Guopu Xu, Puyuan Gao, Huilan Li, Yuanying Fang and Zunhua Yang

European Journal of Medicinal Chemistry, 2026, 309, 118770
DOI: 10.1016/j.ejmech.2026.118770

Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin–Proteasome system

Hanshu Xie and Chao Zhang

European Journal of Medicinal Chemistry, 2024, 267, 116168
DOI: 10.1016/j.ejmech.2024.116168

Degradation of Hexokinase 2 Blocks Glycolysis and Induces GSDME-Dependent Pyroptosis to Amplify Immunogenic Cell Death for Breast Cancer Therapy

Ruoxi Sang, Renming Fan, Aohua Deng, Jiakui Gou, Ruizhuo Lin, Ting Zhao, Yongrui Hai, Junke Song, Yang Liu, Bing Qi, Guanhua Du, Maosheng Cheng and Gaofei Wei

J. Med. Chem., 2023, 66, 8464
DOI: 10.1021/acs.jmedchem.3c00118

UNC-45A: A potential therapeutic target for malignant tumors

Hong Wang and Fude Sun

Heliyon, 2024, 10, e31276
DOI: 10.1016/j.heliyon.2024.e31276

PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators

Sunny Periyasamy, Thyla Jarrett, Joe Truong and Rachid Skouta

Journal of Enzyme Inhibition and Medicinal Chemistry, 2026, 41
DOI: 10.1080/14756366.2026.2636394

Remodeling the Physicochemical and Pharmacokinetic Properties of PROTAC via Lipid Nanodisks for Cancer Therapy

Meichen Pan, Chunrong Yang, Zhongliang Fu, Yuchen Yang, Ying Zhuo, Hongwei Hou and Jinghong Li

Advanced Science, 2025, 12
DOI: 10.1002/advs.202501384

Expanding the druggable proteome strategies and innovations in targeted protein degradation

Ke Ma, Ting Liu, Wen-Bo Huan, Ke-Zheng Chen and Sheng-Lin Qiao

Nano Today, 2026, 67, 102945
DOI: 10.1016/j.nantod.2025.102945

Multimodal supramolecular targeting chimeras enable spatiotemporally resolved protein degradation in vivo

Ji Liu, Tianyu Ma, Rui Yao, Lijuan Li, Qizhen Zheng and Ming Wang

Cell, 2026, 189, 1108
DOI: 10.1016/j.cell.2025.12.007

A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity

Ying Kong, Xinyue Zhao, Zhaofu Wang, Siqi Yuan, Sheng Chen, Shidi Lou, Shichao Ma, Yunfeng Li, Xinghao Wang, Yangfeng Ge, Guobin Li, Hongbing Yang, Mengxi Zhao, Dandan Li, Hailong Zhang, Wenfu Tan and Juan Wang

Molecular Cancer Therapeutics, 2024, 23, 1084
DOI: 10.1158/1535-7163.MCT-23-0719

Tandem‐Activatable PROTAC Prodrug for Tumor Biomarker‐Driven Near‐Infrared Opto‐Proteolysis

Xiaoyan Lu, Xiaoning Wang, Hanwen Liao, Baitong Sha, Yan Zhang and Jinbo Li

Angew Chem Int Ed, 2025, 64
DOI: 10.1002/anie.202510641

Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)

Huifang Wang, Runhua Zhou, Fushan Xu, Kongjun Yang, Liuhai Zheng, Pan Zhao, Guangwei Shi, Lingyun Dai, Chengchao Xu, Le Yu, Zhijie Li, Jianhong Wang and Jigang Wang

Biomater Res, 2023, 27
DOI: 10.1186/s40824-023-00385-8

PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery

Nicolas Guedeney, Marie Cornu, Florian Schwalen, Charline Kieffer and Anne Sophie Voisin-Chiret

Drug Discovery Today, 2023, 28, 103395
DOI: 10.1016/j.drudis.2022.103395

Nanoparticle-mediated targeting chimeras transform targeted protein degradation

Yang Liu, Xue Xia, Yunjiao Zhang, Meng Zheng, Kam W. Leong and Bingyang Shi

Nat. Nanotechnol., 2026, 21, 176
DOI: 10.1038/s41565-025-02081-1

Modulating the phosphorylation status of target proteins through bifunctional molecules

Qindi He, Zhijie Wang, Rongrong Wang, Tao Lu, Yadong Chen and Shuai Lu

Drug Discovery Today, 2025, 30, 104307
DOI: 10.1016/j.drudis.2025.104307

LYMTACs:chimeric small molecules repurpose lysosomal membrane proteins for target protein relocalization and degradation

Dhanusha A. Nalawansha, Georgios Mazis, Gitte Husemoen, Kate S. Ashton, Weixian Deng, Ryan P. Wurz, Anh T. Tran, Brian A. Lanman, Jiansong Xie, Robert G. Guenette, Shiqian Li, Christopher E. Smith, Suresh Archunan, Manoj K. Agnihotram, Arghya Sadhukhan, Rajiv Kapoor, Chris Wilde, Sajjan Koirala, Felipe De Sousa E Melo and Patrick Ryan Potts

Nat Commun, 2025, 16
DOI: 10.1038/s41467-025-63128-4

Targeted protein degradation with bifunctional molecules as a novel therapeutic modality for Alzheimer's disease & beyond

C. Alexander Sandhof, Heide F.B. Murray, M. Catarina Silva and Stephen J. Haggarty

Neurotherapeutics, 2025, 22, e00499
DOI: 10.1016/j.neurot.2024.e00499

FTO degrader impairs ribosome biogenesis and protein translation in acute myeloid leukemia

Wenlong Li, Yutao Zhao, Dong Wu, Zhenhua Chen, Ying Qing, Fan Yang, Fei Ji, Linda Zhang, Lillian Sau, Jianjun Chen and Chuan He

Sci. Adv., 2025, 11
DOI: 10.1126/sciadv.adv7648

Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands

Hanqiao Xu, Takashi Kurohara, Nobumichi Ohoka, Genichiro Tsuji, Takao Inoue, Mikihiko Naito and Yosuke Demizu

Bioorganic & Medicinal Chemistry, 2023, 86, 117293
DOI: 10.1016/j.bmc.2023.117293

Advances in Ubiquitination and Proteostasis in Retinal Degeneration

Jia Wei, Xiaona Chen, Yingyue Xiong and Yali Gao

Front. Biosci. (Landmark Ed), 2024, 29
DOI: 10.31083/j.fbl2907260

Design, synthesis, and biological evaluation of death-associated protein kinase 1 PROTACs

Xueyin Wu, Ruomeng Li, Wujin Tian, Jing Yao, Dongmei Chen, Tae Ho Lee and Yang Liu

Bioorganic Chemistry, 2025, 165, 109044
DOI: 10.1016/j.bioorg.2025.109044

Development of PROTACS degrading KRAS and SOS1

GERHARD HAMILTON, MARIE-THERESE EGGERSTORFER and SANDRA STICKLER

OR, 2024, 32, 1257
DOI: 10.32604/or.2024.051653

Diversified design strategies for small-molecule PROTACs: How do we select?

Qing-Song Chen and Jian-Hua Liang

European Journal of Medicinal Chemistry, 2026, 306, 118593
DOI: 10.1016/j.ejmech.2026.118593

Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment

Md Sadique Hussain, Liming Zhang, Amita Joshi Rana, Mudasir Maqbool, Sumel Ashique, Yumna Khan, Vikas Jakhmola, Ali Hanbashi, Wedad Mawkili and Gyas Khan

Future Medicinal Chemistry, 2025, 17, 1725
DOI: 10.1080/17568919.2025.2533113

Targeted degradation of LRG1 to attenuate renal fibrosis

Linyao Fan, Yingqiu Qi, Xi Yang, Yarui Xu, Yana Zhang, Longdi Wang, Anying Zhu, Lirong Zhang, Jian Song, Shengnan Du, Guangjun Nie and Huan Min

Asian Journal of Pharmaceutical Sciences, 2024, 19, 100941
DOI: 10.1016/j.ajps.2024.100941

Dual‐Programmable Semiconducting Polymer NanoPROTACs for Deep‐Tissue Sonodynamic‐Ferroptosis Activatable Immunotherapy

Fengshuo Wang, Guoqiang Dong, Mengbin Ding, Ningyue Yu, Chunquan Sheng and Jingchao Li

Small, 2024, 20
DOI: 10.1002/smll.202306378

A comprehensive primer and review of PROTACs and their In Silico design

Jacopo Zattoni, Paola Vottero, Gea Carena, Chiara Uliveto, Giulia Pozzati, Benedetta Morabito, Ebenezea Gitari, Jack Tuszynski and Maral Aminpour

Computer Methods and Programs in Biomedicine, 2025, 264, 108687
DOI: 10.1016/j.cmpb.2025.108687

The Role of Reactive Oxygen Species in Lung Cancer Development: Nanomedicine as a Therapeutic Strategy

Manuel Olazábal-Morán, Elena Pérez, Adrián Esteban-Arranz and Antonio Garrido

Biomolecules, 2025, 15, 1316
DOI: 10.3390/biom15091316

Discovery and Optimization of Potent PROTAC Degraders of Phosphoinositide 3-Kinase with Significant in Vivo Anticancer Efficacy

Shouguo Peng, Qinghua Zhang, Hua Tian, Jingbo Zhang, Jialing Deng, Haixiang Qi, Deyu Wu, Tingting Du, Kehui Zhang, Junpu Ge, Li Sheng, Songwen Lin, Ming Ji and Heng Xu

J. Med. Chem., 2025, 68, 12800
DOI: 10.1021/acs.jmedchem.5c00679

Progress in the Development of PROTAC Degraders of FLT3

Bohai Fan, Licheng Zhou, Yuanyuan Xie, Weixue Huang and Zhen Wang

ChemistrySelect, 2025, 10
DOI: 10.1002/slct.202503917

PROTAC-powered synergistic tumor therapy

Xiaoyu Wang, Jingwen Zou, Yixuan Tao, Zhiwen Zhou, Changyu Bian, Zhiqiang Mao and Zhihong Liu

TrAC Trends in Analytical Chemistry, 2026, 196, 118678
DOI: 10.1016/j.trac.2026.118678

Current strategies for improving limitations of proteolysis targeting chimeras

Chunlan Pu, Shirui Wang, Lei Liu, Zhonghui Feng, Hongjia Zhang, Qianyuan Gong, Yueshan Sun, Yuanbiao Guo and Rui Li

Chinese Chemical Letters, 2023, 34, 107927
DOI: 10.1016/j.cclet.2022.107927

Interplay of epigenetics and epistasis drives oral submucous fibrosis

Mohit Sharma, Smitha Sammith Shetty, Faisal Alhedyan and Raghu Radhakrishnan

Discov Appl Sci, 2025, 7
DOI: 10.1007/s42452-025-07571-4

Discovery of a bifunctional PKMYT1-targeting PROTAC empowered by AI-generation

Yazhou Wang, Xiaomin Wang, Tingting Liu, Chao Wang, Qingshuo Meng, Fanye Meng, Jiaojiao Yu, Jinxin Liu, Yaya Fan, David Gennert, Frank W. Pun, Alex Aliper, Feng Ren, Man Zhang, Xin Cai, Xiao Ding and Alex Zhavoronkov

Nat Commun, 2025, 16
DOI: 10.1038/s41467-025-65796-8

Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins

Junius Eugene Thomas, Mi Wang, Wei Jiang, Meilin Wang, Lu Wang, Bo Wen, Duxin Sun and Shaomeng Wang

J. Med. Chem., 2023, 66, 8178
DOI: 10.1021/acs.jmedchem.3c00492

Elucidating biased signaling in class A GPCRs

Ningyang Xu, Edwin Legall, Roger H. Johnson, Lan Zhu and Wei Liu

Trends in Pharmacological Sciences, 2025, 46, 1190
DOI: 10.1016/j.tips.2025.10.008

Staudinger Reaction-Responsive Coacervates for Cytosolic Antibody Delivery and TRIM21-Mediated Protein Degradation

Yishu Bao, Zhiyi Xu, Kai Cheng, Xiaojing Li, Fangke Chen, Dingdong Yuan, Fang Zhang, Audrey Run-Yu Che, Xiangze Zeng, Yuan-Di Zhao and Jiang Xia

J. Am. Chem. Soc., 2025, 147, 3830
DOI: 10.1021/jacs.4c17054

Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications

Qiong Li, Li Zhou, Siyuan Qin, Zhao Huang, Bowen Li, Ruolan Liu, Mei Yang, Edouard C. Nice, Huili Zhu and Canhua Huang

European Journal of Medicinal Chemistry, 2023, 257, 115447
DOI: 10.1016/j.ejmech.2023.115447

Leveraging aptamers for targeted protein degradation

Zhihao Yang, Qiuxiang Pang, Jun Zhou, Chenghao Xuan and Songbo Xie

Trends in Pharmacological Sciences, 2023, 44, 776
DOI: 10.1016/j.tips.2023.05.008

Autophagy-Activating Nanoautophagosome-Tethering Compounds for Targeted Protein Degradation Specifically in Tumor Cells

Mengchen Xu, Jiajing Chen, Shuyu Wang, Linlin Xu, Xiaohui Wu, Jinpu Yu, Feihe Ma and Linqi Shi

ACS Macro Lett., 2025, 14, 250
DOI: 10.1021/acsmacrolett.4c00789

Multifaceted roles of HDAC7 in disease and the evolving chemical toolkit for its modulation

Wenwen Nie, Baoli Ding, Xiaotong Chen, Li Jiang, Qiaojun He, Ji Cao and Cheng-Liang Zhu

Bioorganic & Medicinal Chemistry Letters, 2026, 132, 130510
DOI: 10.1016/j.bmcl.2025.130510

Emerging methods to improve PROTAC transport across cell membrane

Fatemeh Veisi and Farangis Ataei

Chemical Engineering Journal, 2026, 530, 173175
DOI: 10.1016/j.cej.2026.173175

A pharmacological modality to sequester homomeric proteins

Ella Livnah, Ohad Suss, Adi Rogel, Atar Gilat, Yuval Abdan, José A. Villegas, Ronen Gabizon, Almog Nadir, Yoav Shamir, Noam Y. Steinman, Barr Tivon, Shira Albeck, Tamar Unger, Ofra Golani, Inna Goliand, Nadav Elad, Silvia Carvalho, Khriesto Shurrush, Haim Barr, David Margulies, Emmanuel D. Levy and Nir London

Nat Chem Biol, 2026
DOI: 10.1038/s41589-026-02141-0

PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives

André T. S. Vicente and Jorge A. R. Salvador

MedComm, 2024, 5
DOI: 10.1002/mco2.575

Medicinal Chemistry Education: Emphasize Fundamentals and Skillfully Integrate Knowledge

Shaoqing Du, Xueping Hu, Craig W. Lindsley and Peng Zhan

J. Med. Chem., 2024, 67, 19929
DOI: 10.1021/acs.jmedchem.4c02622

De Novo Design of Hexamer‐Linker Dual‐Action Nano‐PROTAC for Tumor‐Specific Ferroptosis

Ni‐Yuan Zhang, Zhuan Wen, Ming‐Ze Cai, Ke‐Ting Zhou, Hao‐Ze Li, Yi‐xuan Liu, Shang Wu, Yu Xia, Hong‐Wei An and Hao Wang

Angewandte Chemie, 2026, 138
DOI: 10.1002/ange.202509924

Recent Advances in PROTAC Technology Toward New Therapeutic Modalities

Hidetomo Yokoo, Miyako Naganuma, Makoto Oba and Yosuke Demizu

Chemistry & Biodiversity, 2022, 19
DOI: 10.1002/cbdv.202200828

Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach

Qiuxia Chen, Chuan Liu, Wei Wang, Xiaoyun Meng, Xuemin Cheng, Xianyang Li, Longying Cai, Linfu Luo, Xu He, Huan Qu, Jing Luo, Hong Wei, Sen Gao, Guansai Liu, Jinqiao Wan, David I. Israel, Jin Li and Dengfeng Dou

ACS Chem. Biol., 2023, 18, 25
DOI: 10.1021/acschembio.2c00797

Computational methods and key considerations for in silico design of proteolysis targeting chimera (PROTACs)

Amr Abbas and Fei Ye

International Journal of Biological Macromolecules, 2024, 277, 134293
DOI: 10.1016/j.ijbiomac.2024.134293

Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies

Xiaopeng Peng, Zhihao Hu, Limei Zeng, Meizhu Zhang, Congcong Xu, Benyan Lu, Chengpeng Tao, Weiming Chen, Wen Hou, Kui Cheng, Huichang Bi, Wanyi Pan and Jianjun Chen

Acta Pharmaceutica Sinica B, 2024, 14, 533
DOI: 10.1016/j.apsb.2023.09.003

Self-assembled PROTACs enable protein degradation to reprogram the tumor microenvironment for synergistically enhanced colorectal cancer immunotherapy

Xinchen Lu, Jinmei Jin, Ye Wu, Jiayi Lin, Xiaokun Zhang, Shengxin Lu, Jiyuan Zhang, Chunling Zhang, Maomao Ren, Hongzhuan Chen, Weidong Zhang and Xin Luan

Bioactive Materials, 2025, 43, 255
DOI: 10.1016/j.bioactmat.2024.09.022

PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer

Kailee A. Rutherford and Kirk J. McManus

Molecular Cancer Therapeutics, 2024, 23, 454
DOI: 10.1158/1535-7163.MCT-23-0747

Design and evaluation of anaplastic lymphoma kinase degraders using a covalent fumarate handle

Namsik Yu, Ji-Eun Lee, Seulki Park, Su Kyeong Yun, Do Hyun Ryu, Jung-Ae Kim, Jeong-Hoon Kim and Jong Yeon Hwang

Bioorganic & Medicinal Chemistry Letters, 2025, 117, 130075
DOI: 10.1016/j.bmcl.2024.130075

Development of a Selective and Potent PRMT4 PROTAC Degrader with Efficacy against Multiple Myeloma in Vitro and in Vivo

Yong Ju, Huizhu Song, Yuelan He, Yingtung Lo, Zhipeng Fan and Jianzhong Lu

J. Med. Chem., 2025, 68, 13973
DOI: 10.1021/acs.jmedchem.5c01022

Combinatorial Ubiquitination REal-time PROteolysis (CURE-PROs): A Modular Platform for Generating Reversible, Self-Assembling Bifunctional Targeted Degraders

Sarah F. Giardina, Elena Valdambrini, Pradeep K. Singh, Manny D. Bacolod, Ganesh Babu-Karunakaran, Michael Peel, J. David Warren and Francis Barany

J. Med. Chem., 2024, 67, 5473
DOI: 10.1021/acs.jmedchem.3c02097

Carrier-Free Nano-PROTACs to Amplify Photodynamic Therapy Induced DNA Damage through BRD4 Degradation

Lin-Ping Zhao, Xiao-Na Rao, Rong-Rong Zheng, Chu-Yu Huang, Ren-Jiang Kong, Hong Cheng, Bin Li and Shi-Ying Li

Nano Lett., 2023, 23, 6193
DOI: 10.1021/acs.nanolett.3c01812

Central Nervous System Targeted Protein Degraders

Bedwyr ab Ion Thomas, H. Lois Lewis, D. Heulyn Jones and Simon E. Ward

Biomolecules, 2023, 13, 1164
DOI: 10.3390/biom13081164

DNA polymerase theta in cancer therapy: mechanism of action and modulator development

Junwei Wu, Yi Xu and Linlin Xiao

Biochemical Pharmacology, 2026, 243, 117513
DOI: 10.1016/j.bcp.2025.117513

ClickRNA-PROTAC for Tumor-Selective Protein Degradation and Targeted Cancer Therapy

Xucong Teng, Xuan Zhao, Yicong Dai, Xiangdong Zhang, Qiushuang Zhang, Yuncong Wu, Difei Hu and Jinghong Li

J. Am. Chem. Soc., 2024, 146, 27382
DOI: 10.1021/jacs.4c06402

Strategies for Precise Modulation of Protein Degradation

Shipeng He, Guoqiang Dong and Chunquan Sheng

Acc. Chem. Res., 2025, 58, 1236
DOI: 10.1021/acs.accounts.5c00003

Advancing cancer immunotherapy: Small-Molecule, biomacromolecular, and nanoscale PROTACs targeting PD-L1 for degradation

Yang Meng, Yujing Zhang, Wanpeng Yu, Dongming Xing and Chao Wang

Materials Today Advances, 2025, 27, 100606
DOI: 10.1016/j.mtadv.2025.100606

Small-Molecule Modulators Targeting Coactivator-Associated Arginine Methyltransferase 1 (CARM1) as Therapeutic Agents for Cancer Treatment: Current Medicinal Chemistry Insights and Emerging Opportunities

Shuqing Li, Wanyi Pan, Chengpeng Tao, Zhihao Hu, Binbin Cheng, Jianjun Chen and Xiaopeng Peng

J. Med. Chem., 2025, 68, 5024
DOI: 10.1021/acs.jmedchem.4c02106

Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy

Ritesh P. Bhole, Payal R. Kute, Rupesh V. Chikhale, C.G. Bonde, Amit Pant and Shailendra S. Gurav

Bioorganic Chemistry, 2023, 139, 106720
DOI: 10.1016/j.bioorg.2023.106720

Recent advances in developing targeted protein degraders

Binbin Cheng, Hongqiao Li, Xiaopeng Peng, Jianjun Chen, Chuxiao Shao and Zhihua Kong

European Journal of Medicinal Chemistry, 2025, 284, 117212
DOI: 10.1016/j.ejmech.2024.117212

De Novo Design of Hexamer‐Linker Dual‐Action Nano‐PROTAC for Tumor‐Specific Ferroptosis

Ni‐Yuan Zhang, Zhuan Wen, Ming‐Ze Cai, Ke‐Ting Zhou, Hao‐Ze Li, Yi‐xuan Liu, Shang Wu, Yu Xia, Hong‐Wei An and Hao Wang

Angew Chem Int Ed, 2026, 65
DOI: 10.1002/anie.202509924

Unhooking the Hook: Optimization of the Aurora A Targeting PROTAC JB170 to CCT400028, an In Vitro Degrader Chemical Probe

Jack A. O’Hanlon, Katrin Gutsche, Juliane Elisabeth Müller, Nihar Ranjan Prusty, Amin Mirza, Theodoros I. Roumeliotis, Hengzhang Yang, Mark Stubbs, Stephen T. Hallett, Lorenz Eing, Peter Craig McAndrew, Jyoti Sharma Choudhary, Yann-Vaï Le Bihan, John Caldwell, Rob L. M. van Montfort, Paul Workman, Elmar Wolf, Gary K. Newton and Lindsay E. Evans

J. Med. Chem., 2026, 69, 1552
DOI: 10.1021/acs.jmedchem.5c03024

BRD4 Degradation Enhanced Glioma Sensitivity to Temozolomide by Regulating Notch1 via Glu‐Modified GSH‐Responsive Nanoparticles

Linbin Yi, Zhenyu Zhang, Wenjie Zhou, Yunchu Zhang, Yuzhu Hu, Anjie Guo, Yongzhong Cheng, Zhiyong Qian, Peizhi Zhou and Xiang Gao

Advanced Science, 2024, 11
DOI: 10.1002/advs.202409753

New-generation advanced Nano-PROTACs as potential therapeutic agents in cancer therapy

Jingjuan Zhang, Yongzheng Li, Huiyuan Jin, Peizhen Yang, Huan Min, Jian Song and Yingqiu Qi

Journal of Controlled Release, 2026, 392, 114673
DOI: 10.1016/j.jconrel.2026.114673

A Medicinal Chemistry Perspective on Lactate Dehydrogenase: Current Status and Future Directions

Wanyi Pan, Chengpeng Tao, Yi Wu and Feng Jiang

J. Med. Chem., 2025, 68, 16869
DOI: 10.1021/acs.jmedchem.5c00182

Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research

Xiang Li, Qian Liu, Xin Xie, Cheng Peng, Qiwen Pang, Bo Liu and Bo Han

J. Med. Chem., 2023, 66, 1700
DOI: 10.1021/acs.jmedchem.2c01712

Discovery of an Exceptionally Orally Bioavailable and Potent HPK1 PROTAC with Enhancement of Antitumor Efficacy of Anti-PD-L1 Therapy

Mingfei Wu, Yiquan Wu, Yuyuan Jin, Xinfei Mao, Shenxin Zeng, Hengyuan Yu, Jingyu Zhang, Yuheng Jin, Yizhe Wu, Tengfei Xu, Yong Chen, Yuwei Wang, Xiaojun Yao, Jinxin Che, Wenhai Huang and Xiaowu Dong

J. Med. Chem., 2024, 67, 13852
DOI: 10.1021/acs.jmedchem.4c00644

Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions

Gang Fan, Shilin Chen, Qingping Zhang, Na Yu, Ziyang Shen, Zhaoji Liu, Weiming Guo, Zhihan Tang, Jing Yang and Miao Liu

MedComm, 2025, 6
DOI: 10.1002/mco2.70401

Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs

Rui Yao, Tianli Luo and Ming Wang

ChemBioChem, 2023, 24
DOI: 10.1002/cbic.202300413

Peptide-based PROTACs: Current Challenges and Future Perspectives

Huidan Wang, Miao Chen, Xiaoyuan Zhang, Songbo Xie, Jie Qin and Jingrui Li

CMC, 2024, 31, 208
DOI: 10.2174/0929867330666230130121822

Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia

Tianbang Wu, Jiankang Hu, Xiaofan Zhao, Cheng Zhang, Ruibo Dong, Qingqing Hu, Hongrui Xu, Hui Shen, Xiaohan Zhang, Yan Zhang, Bin Lin, Xishan Wu, Qiuping Xiang and Yong Xu

J. Med. Chem., 2024, 67, 9194
DOI: 10.1021/acs.jmedchem.4c00335

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Noé Herbel and Sophie Postel‐Vinay

Molecular Oncology, 2025, 19, 2461
DOI: 10.1002/1878-0261.70034

Application of PROTACs in target identification and validation

Yang Liu, Jing Liang, Rui Zhu, Yueying Yang, Yali Wang, Wenyi Wei, Hua Li and Lixia Chen

Acta Materia Medica, 2024, 3
DOI: 10.15212/AMM-2024-0010

Deciphering the dynamics of histone acetylation and chromatin remodeling in multiple myeloma: a tale beyond the tails

Sinan Xiong, Jianbiao Zhou and Wee-Joo Chng

Blood, 2025, 146, 1550
DOI: 10.1182/blood.2025028403

Molecular glue degraders: Rational design, specificity engineering, and advanced delivery

Lieen Ma, Ning Wang, Jingjing Zhu, Lingjie Wu, Shan He and Bin Zhang

Acta Pharmaceutica Sinica B, 2026
DOI: 10.1016/j.apsb.2026.02.020

A potent and selective PROTAC degrader of CDK9 as effective inhibitor of HIV-1 RNA synthesis

Bo Yang, Ling Ma, Xiaotang Yang, Jiajia Wen, Weiyi Yin, Siqi Li, Yingjie Ji, Ying Wang, Shan Cen and Yanping Li

Mol Divers, 2025
DOI: 10.1007/s11030-025-11393-2

Exploiting ELIOT for Scaffold-Repurposing Opportunities: TRIM33 a Possible Novel E3 Ligase to Expand the Toolbox for PROTAC Design

Tommaso Palomba, Giusy Tassone, Carmine Vacca, Matteo Bartalucci, Aurora Valeri, Cecilia Pozzi, Simon Cross, Lydia Siragusa and Jenny Desantis

IJMS, 2022, 23, 14218
DOI: 10.3390/ijms232214218

Antibody-Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor-Interacting Serine/Threonine-Protein Kinase 2 in HER2+ Cell Lines

Karina Chan, Preethi Soundarya Sathyamurthi, Markus A. Queisser, Michael Mullin, Harry Shrives, Diane M. Coe and Glenn A. Burley

Bioconjugate Chem., 2023, 34, 2049
DOI: 10.1021/acs.bioconjchem.3c00366

E3 ubiquitin ligases and their therapeutic potential in disease Management

Geet Madhukar, Md Azizul Haque, Shawez Khan, Jong-Joo Kim and Danishuddin

Biochemical Pharmacology, 2025, 236, 116875
DOI: 10.1016/j.bcp.2025.116875

Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery

He Tang, Lin Wang, Tianyu Wang, Jiamei Yang, Shuai Zheng, Jun Tong, Sheng Jiang, Xiangyu Zhang and Kuojun Zhang

European Journal of Medicinal Chemistry, 2023, 258, 115607
DOI: 10.1016/j.ejmech.2023.115607

Strategies and techniques for preclinical therapeutic targeting of PI3K in oncology: where do we stand in 2024?

Yanyan Liu, Qiu Sun and Xiawei Wei

Expert Opinion on Therapeutic Targets, 2024, 28, 221
DOI: 10.1080/14728222.2024.2342522

TAC‐tics for Leveraging Proximity Biology in Drug Discovery

Dhanusha A. Nalawansha, Kyle Mangano, Willem den Besten and Patrick Ryan Potts

ChemBioChem, 2024, 25
DOI: 10.1002/cbic.202300712

New-generation advanced PROTACs as potential therapeutic agents in cancer therapy

Chao Wang, Yujing Zhang, Wujun Chen, Yudong Wu and Dongming Xing

Mol Cancer, 2024, 23
DOI: 10.1186/s12943-024-02024-9

TRL-PROTAC: A pre-trained generator of PROTACs targeting specific proteins optimized by reinforcement learning

Yuhao Dai and Fei Zhu

ComSIS, 2024, 21, 1293
DOI: 10.2298/CSIS240327039D

Kinase-Bench: Comprehensive Benchmarking Tools and Guidance for Achieving Selectivity in Kinase Drug Discovery

Tian-Hua Wei, Shuang-Shuang Zhou, Xiao-Long Jing, Jia-Chuan Liu, Meng Sun, Zong-Hao Zhao, Qing-Qing Li, Zi-Xuan Wang, Jin Yang, Yun Zhou, Xue Wang, Cheng-Xiao Ling, Ning Ding, Xin Xue, Yan-Cheng Yu, Xiao-Long Wang, Xiao-Ying Yin, Shan-Liang Sun, Peng Cao, Nian-Guang Li and Zhi-Hao Shi

J. Chem. Inf. Model., 2024, 64, 9528
DOI: 10.1021/acs.jcim.4c01830

Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy

Yue Song, Qing-Qing Dong, Yi-Ke Ni, Xiao-Ling Xu, Chao-Xiang Chen and Wei Chen

IJN, 2024, Volume 19, 5739
DOI: 10.2147/IJN.S448684

PSMA-Guided PROTAC Degraders for Tumor-Specific Protein Degradation in Prostate Cancer

Xiaolei Meng, Xiaolin Hu, Shan Gao, Wenrui Jia, Sai Zhang, Siqi Zhang, Xiao Wang, Shumin Ma and Chong Qin

J. Med. Chem., 2025, 68, 10139
DOI: 10.1021/acs.jmedchem.5c00226

Tandem‐Activatable PROTAC Prodrug for Tumor Biomarker‐Driven Near‐Infrared Opto‐Proteolysis

Xiaoyan Lu, Xiaoning Wang, Hanwen Liao, Baitong Sha, Yan Zhang and Jinbo Li

Angewandte Chemie, 2025, 137
DOI: 10.1002/ange.202510641

High‐Throughput Miniaturized Synthesis of PROTAC‐Like Molecules

Ye Tian, Maximilian Seifermann, Liana Bauer, Charlotte Luchena, Janne J. Wiedmann, Stefan Schmidt, Alexander Geisel, Sergii Afonin, Julius Höpfner, Marius Brehm, Xinyong Liu, Carsten Hopf, Anna A. Popova and Pavel A. Levkin

Small, 2024, 20
DOI: 10.1002/smll.202307215

The Discovery of a Specific CKIP-1 Ligand for the Potential Treatment of Disuse Osteoporosis

Yange Wei, Bo Wu, Mingqiu Liu and Chun-Ping Cui

IJMS, 2024, 25, 8870
DOI: 10.3390/ijms25168870

Discovery of Ligands for TRIM58, a Novel Tissue-Selective E3 Ligase

Klemens Hoegenauer, Shaojian An, Jake Axford, Christina Benander, Christian Bergsdorf, Josephine Botsch, Suzanne Chau, César Fernández, Scott Gleim, Ulrich Hassiepen, Juerg Hunziker, Emilie Joly, Aramis Keller, Sandra Lopez Romero, Robert Maher, Anne-Sophie Mangold, Craig Mickanin, Manuel Mihalic, Philippe Neuner, Andrew W. Patterson, Francesca Perruccio, Silvio Roggo, Julien Scesa, Martin Schröder, Dojna Shkoza, Binh Thai, Anna Vulpetti, Martin Renatus and John S. Reece-Hoyes

ACS Med. Chem. Lett., 2023, 14, 1631
DOI: 10.1021/acsmedchemlett.3c00259

Enhancing cancer therapy: The role of drug delivery systems in STAT3 inhibitor efficacy and safety

Kang-Ning Wang, Kan Zhou, Nian-Nian Zhong, Lei-Ming Cao, Zi-Zhan Li, Yao Xiao, Guang-Rui Wang, Fang-Yi Huo, Jun-Jie Zhou, Bing Liu and Lin-Lin Bu

Life Sciences, 2024, 346, 122635
DOI: 10.1016/j.lfs.2024.122635

Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies

Jifa Zhang, Yinglu Zhang, Jiaxing Wang, Yilin Xia, Jiaxian Zhang and Lei Chen

Sig Transduct Target Ther, 2024, 9
DOI: 10.1038/s41392-024-01911-3

PROTACs in the Management of Prostate Cancer

Poornachandra Yedla, Ahmed O. Babalghith, Vindhya Vasini Andra and Riyaz Syed

Molecules, 2023, 28, 3698
DOI: 10.3390/molecules28093698

Rational engineering of degradation tail-driven CELMoD–antibody conjugates for precision malignancy therapy

Yu Guo, Yi Song, Hanlin Wang, Yang Lu, Jingyu Zhang, Zheyuan Shen, Weijuan Kan, Yuxian Wang, Haiting Duan, Shuangshuang Geng, Bo Wang, Shaoting Li, Bizhi Li, Xi Chen, Shanshan Pei, Luo Fang, Jia Li, Yubo Zhou, Jinxin Che and Xiaowu Dong

Acta Pharmaceutica Sinica B, 2025, 15, 6510
DOI: 10.1016/j.apsb.2025.09.009

2-Aminobenzothiazoles in anticancer drug design and discovery

Guang Huang, Tomasz Cierpicki and Jolanta Grembecka

Bioorganic Chemistry, 2023, 135, 106477
DOI: 10.1016/j.bioorg.2023.106477

Macrophage MCT4 inhibition activates reparative genes and protects from atherosclerosis by histone H3 lysine 18 lactylation

Yunjia Zhang, Hong Jiang, Mengdie Dong, Jiao Min, Xian He, Yongkang Tan, Fuhao Liu, Minghong Chen, Xiang Chen, Quanwen Yin, Longbin Zheng, Yongfeng Shao, Xuesong Li and Hongshan Chen

Cell Reports, 2024, 43, 114180
DOI: 10.1016/j.celrep.2024.114180

Application of mass spectrometry for the advancement of PROTACs

Yuechen Hao, Baoshuang Zhang and Ruibing Chen

Journal of Pharmaceutical and Biomedical Analysis, 2025, 261, 116829
DOI: 10.1016/j.jpba.2025.116829

Unraveling the secrets of novel PROTACs to improve degradation efficacy

Juan Huang, Xiaoyan Yang, Qiuqian Huang, Yangyang Gao, Pradeepa C. G. Bandaranayake, Wishwajith Kandegama, Charles R. Ashby, Yawen Dong, Zhenchao Wang and Ge-Fei Hao

Mol Divers, 2025
DOI: 10.1007/s11030-025-11273-9

Albumin-encapsulated HSP90-PROTAC BP3 nanoparticles not only retain protein degradation ability but also enhance the antitumour activity of BP3 in vivo

Qingna Jiang, Yan Hu, Quanyu Liu, Yuanling Tang, Xinhua Wu, Jingwen Liu, Guihui Tu, Ge Li, Xiaoqing Lin, Minghui Qu, Yajuan Cai, Xiuwang Huang, Jianhua Xu, Yanping Deng, Zhuo Chen and Lixian Wu

Journal of Drug Targeting, 2023, 31, 411
DOI: 10.1080/1061186X.2023.2185247

Why does EGFR-targeted therapy continue to fail in breast cancer? From mechanistic deciphering to novel intervention strategies

Xiaoli An, Jie Xie, Weiyun Wang, Ting Long, Qinhao Liang and Jing Hou

Critical Reviews in Oncology/Hematology, 2026, 220, 105186
DOI: 10.1016/j.critrevonc.2026.105186

From Invaginating Site to Deep Lesion: Spatial Transcriptomics Unravels Ectopic Endometrial Penetration Features in Adenomyosis

Boyu Li, Jia Qi, Yumeng Cao, Yijing Long, Zhe Wei, Wang‐Sheng Wang, Shuanggang Hu, Yuan Wang, Qinling Zhu, Xiao Hu, Zhe Sun, Jie Zhu, Taiyang Ye, Yejie Yao, Yiwen Meng, Xuejiao Bian, Xinyi Dong, Hengyu Guan, Yunfei Huang and Yun Sun

Advanced Science, 2025, 12
DOI: 10.1002/advs.202411752

Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques

Siyu Chen, Jingliang Cui, Haiyan Chen, Bo Yu and Sihui Long

European Journal of Medicinal Chemistry, 2023, 262, 115911
DOI: 10.1016/j.ejmech.2023.115911

EGFR Targeted Liposomal PROTAC Assisted With Epigenetic Regulation as an Efficient Strategy for Osimertinib‐Resistant Lung Cancer Therapy

Dongyuan Wang, Yajing Liu, Ying Chen, Chuan Dai, Wenzhu Hu, Jinyan Han, Zigang Li, Feng Yin, Yu Zhang and Chen Shi

Advanced Science, 2025, 12
DOI: 10.1002/advs.202510197

The Peptide PROTAC Modality: A New Strategy for Drug Discovery

Youmin Zhu, Yu Dai and Yuncai Tian

MedComm, 2025, 6
DOI: 10.1002/mco2.70133

Design and evaluation of selective BET PROTACs with potent antitumor efficacy and safety against acute myeloid leukemia

Qingyun Wei, Jian Zhang, Jiao Chen, Xueting Cai, Jinpei Zhou, Bo Wang, Huibin Zhang and Peng Cao

European Journal of Medicinal Chemistry, 2026, 308, 118667
DOI: 10.1016/j.ejmech.2026.118667

Bioorthogonal Sonodynamic Plug‐and‐Play Targeting Chimeras (SDPTAC) for Precise Targeted Protein Degradation

Yuhan Bao, Yaojin Zhu, Xinhao Wei, Yuxin Fang, Jiayi Zhu, Fei Gao, Guoqiang Dong, Shipeng He and Chunquan Sheng

Advanced Science, 2026, 13
DOI: 10.1002/advs.202520975

Sirtuin 3 as a promising target in disease therapy: Model action and drug discovery

Dongmin Yu

European Journal of Medicinal Chemistry, 2025, 297, 117929
DOI: 10.1016/j.ejmech.2025.117929

Next-generation isoform-selective fibroblast growth factor receptor inhibitors

Lingfeng Chen

Trends in Pharmacological Sciences, 2025, 46, 1091
DOI: 10.1016/j.tips.2025.09.004

Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects

Qin Ru, Yusheng Li, Xi Zhang, Lin Chen, Yuxiang Wu, Junxia Min and Fudi Wang

Bone Res, 2025, 13
DOI: 10.1038/s41413-024-00398-6

CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications

Riya Thapa, Asif Ahmad Bhat, Gaurav Gupta, S. Renuka Jyothi, Irwanjot Kaur, Sachin Kumar, Naveen Sharma, G. V. Siva Prasad, Atreyi Pramanik and Haider Ali

Chem Biol Drug Des, 2024, 104
DOI: 10.1111/cbdd.70009

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Jin Li, Xinxin Chen, Aiping Lu and Chao Liang

The Innovation, 2023, 4, 100413
DOI: 10.1016/j.xinn.2023.100413

Hypoxia-sensitive macrocycle inclusion complexes for targeted protein degradation

Jiachan Lin, Wenyan Wang, An-Kang Ying, Zirui Chen, Dan Zhang, Chendi Ding, Xiaowei Zeng, Dong-Sheng Guo and Hongzhong Chen

Journal of Controlled Release, 2025, 384, 113921
DOI: 10.1016/j.jconrel.2025.113921

Pt(IV)-PROTAC Complexes with Synergistic Antitumor Activity and Enhanced Membrane Permeability

Cheng-xin Li, Zhi-ru Zou, Shan Xu, Jia-hui Shi, Yong Zou, Ming Yan and Xue-jing Zhang

J. Med. Chem., 2025, 68, 8208
DOI: 10.1021/acs.jmedchem.4c02909

The Emergence of Oligonucleotide Building Blocks in the Multispecific Proximity-Inducing Drug Toolbox of Destruction

Kevin Xiao Tong Zhou and Katherine E. Bujold

ACS Chem. Biol., 2025, 20, 3
DOI: 10.1021/acschembio.4c00311

A Medicinal Chemistry Perspective on Protein Tyrosine Phosphatase Nonreceptor Type 2 in Tumor Immunology

Qi Huang, Linghao Hu, Haowen Chen, Bingjie Yang, Xun Sun and Mingliang Wang

J. Med. Chem., 2025, 68, 3995
DOI: 10.1021/acs.jmedchem.4c01802

Multitargeted protein degradation: Integrating small-molecule, biomacromolecular, and nano-PROTACs for paradigm shifts in drug discovery

Jinghua Yang, Yujing Zhang, Miao Zhang, Dongming Xing and Chao Wang

Materials Today Advances, 2025, 28, 100644
DOI: 10.1016/j.mtadv.2025.100644

Fragment-based approaches to discover ligands for tumor-specific E3 ligases

Junhyeong Yim, Solbi Kim, Hyung Ho Lee, Jin Soo Chung and Jongmin Park

Expert Opinion on Drug Discovery, 2024, 19, 1471
DOI: 10.1080/17460441.2024.2415310

Recent Progress in DNA Damage Response-Targeting PROTAC Degraders

Binbin Cheng, Xiaoting Fei, Zongbao Ding, Xiaopeng Peng, Zhenhong Su, Wei Pan and Jianjun Chen

J. Med. Chem., 2024, 67, 6906
DOI: 10.1021/acs.jmedchem.4c00015

Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer

M. Olazábal-Morán, C. Blázquez-Barbadillo, E. Pérez-Izquierdo, M. Muñoz-Silva and A. Garrido

Advanced Drug Delivery Reviews, 2026, 233, 115840
DOI: 10.1016/j.addr.2026.115840

Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes

Jonathan D. Taylor, Nathalie Barrett, Sergio Martinez Cuesta, Katelyn Cassidy, Fiona Pachl, James Dodgson, Radhika Patel, Tuula M. Eriksson, Aidan Riley, Matthew Burrell, Christin Bauer, D. Gareth Rees, Raffaello Cimbro, Andrew X. Zhang, Ralph R. Minter, James Hunt and Sandrine Legg

Commun Biol, 2024, 7
DOI: 10.1038/s42003-024-06803-4

Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution

Yufeng Xiao, Yaxia Yuan, Yi Liu, Zongtao Lin, Guangrong Zheng, Daohong Zhou and Dongwen Lv

J. Med. Chem., 2024, 67, 11580
DOI: 10.1021/acs.jmedchem.4c00723

HerTACs Enable Tumor‐Selective Lysosomal Degradation of Membrane and Extracellular Proteins via HER2 Trafficking

Shipeng He, Wenjing Huang, Yaojin Zhu, Fei Gao, Yuxin Fang, Jiayi Zhu, Yuhan Bao, Guoqiang Dong and Chunquan Sheng

Angewandte Chemie, 2025, 137
DOI: 10.1002/ange.202511467

PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers

Michael Hulse, Min Wang, Chaoyi Xu, Jack Carter, Anjana Agarwal, Liang Lu, Philip Pitis, Neha Bhagwat, Joseph Rager, Justin Kurian, Corey Basch, Monisha Sivakumar, Jessica Burtell, Arpita Mondal, Alexander Grego, Andrew Moore, Carly Bachner, Komali Vykuntam, Anthony Reichelderfer, Jimin Park, Joy Cote, Miles Cowart, Olusola Peace Osinubi, Ludovic Bigot, Alice Da Silva, Catline Nobre, Melissandre Meteau, Miguel Soares, Hsin-Yao Tang, Klare Bersch, Chaofeng Dai, Ganfeng Cao, Bo Shen, Tom Emm, Stefan Ruepp, Jennifer Xavier, Chris Tankersley, Diane Heiser, Sang Hyun Lee, Sandy Geeganage, Bruce Ruggeri, Hong Lin, William Novotny, Jane Huang, Kris Vaddi, Andrew Combs, Peggy Scherle and Koichi Ito

Cancer Research, 2026, 86, 213
DOI: 10.1158/0008-5472.CAN-25-1141

PROTAC-based protein degradation: a window of opportunity for melanoma therapy

Giulia Gentile, Simona D’Aguanno, Marta Di Martile, Adele Petricca, Elisabetta Valentini, Stefano Scalera and Donatella Del Bufalo

J Biomed Sci, 2026, 33
DOI: 10.1186/s12929-026-01225-2

Applications of KinTek Explorer Kinetic Simulations of Targeted Protein Degradation for Evaluation and Design of PROTACs

Yacheng Liu, Jiexin Wu, Danqi Chen and Liang Han

Biochemistry, 2025, 64, 4706
DOI: 10.1021/acs.biochem.5c00381

Mapping the global landscape of molecular glues in drug discovery: a bibliometric analysis from 2010 to 2024

Sonali Labhade, Ritesh Bhole, Pawan Karwa, Harshad Kapare and Subhashini Singh

Naunyn-Schmiedeberg's Arch Pharmacol, 2026, 399, 4321
DOI: 10.1007/s00210-025-04630-w

The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases

Yi-Ru Bai, Wei-Guang Yang, Xue-Hui Hou, Dan-Dan Shen, Sheng-Nan Zhang, Yan Li, Yan-Yan Qiao, Sai-Qi Wang, Shuo Yuan and Hong-Min Liu

European Journal of Medicinal Chemistry, 2023, 258, 115606
DOI: 10.1016/j.ejmech.2023.115606

Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions

Rajamanikkam Kamaraj, Subhrojyoti Ghosh, Souvadra Das, Shinjini Sen, Priyanka Kumar, Madhurima Majumdar, Renesa Dasgupta, Sampurna Mukherjee, Shrimanti Das, Indrilla Ghose, Petr Pavek, Muruga Poopathi Raja Karuppiah, Anil A. Chuturgoon and Krishnan Anand

Bioconjugate Chem., 2024, 35, 1089
DOI: 10.1021/acs.bioconjchem.4c00253

Advancements in PROTAC-based therapies for neurodegenerative diseases

Deyuan Kong, Liying Meng, Pengfei Lin and Guanzhao Wu

Future Medicinal Chemistry, 2025, 17, 591
DOI: 10.1080/17568919.2025.2463310

Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B

Gerrit Wilms, Kevin Schofield, Shayna Maddern, Christopher Foley, Yeng Shaw, Breland Smith, L. Emilia Basantes, Katharina Schwandt, Aaron Babendreyer, Timothy Chavez, Nicholas McKee, Vijay Gokhale, Sebastian Kallabis, Felix Meissner, Samantha N. Rokey, Travis Dunckley, William R. Montfort, Walter Becker and Christopher Hulme

J. Med. Chem., 2024, 67, 17259
DOI: 10.1021/acs.jmedchem.4c01130

Recent advances in targeting protein degradation for tumor immunotherapy

Shuai Li, Yushan Jin, Huanhuan Wu, Hong Yuan and Jingyuan Zhao

J Hematol Oncol, 2025, 19
DOI: 10.1186/s13045-025-01765-4

Discovery of a Potent RXRγ Degrader WCF-598 for the Treatment of Castration-Resistant Prostate Cancer

Chaofan Wang, Jieying Lin, Junping Pei, Zhanfang Kang, Zhuoheng Liu, Junwei Li, Guodi Cai, Yang Zhou, Junjian Wang, Hong Wang and Xiaoyun Lu

J. Med. Chem., 2026
DOI: 10.1021/acs.jmedchem.5c03442

Advances in designing ternary complexes: Integrating in-silico and biochemical methods for PROTAC optimisation in target protein degradation

Shareef Shaik, Prasanna Kumar Reddy Gayam, Manish Chaudhary, Gurvinder Singh and Aravinda Pai

Bioorganic Chemistry, 2024, 153, 107868
DOI: 10.1016/j.bioorg.2024.107868

Integrating Proteolysis‐Targeting Chimeras (PROTACs) with Delivery Systems for More Efficient and Precise Targeted Protein Degradation

Jiachan Lin, Zirui Chen, Dan Zhang, Nan Zhang, Hongzhong Chen and Dong‐Sheng Guo

Macromol. Rapid Commun., 2025, 46
DOI: 10.1002/marc.202401051

Design of bifunctional molecules to accelerate post-translational modifications: achievements and challenges

Yuxuan Wang, Yanyi He, Qidong You and Lei Wang

Drug Discovery Today, 2024, 29, 104194
DOI: 10.1016/j.drudis.2024.104194

Autophagy mediated targeting degradation, a promising strategy in drug development

Jiantao Zhang, Xiangyi Pan, Wenshu Ji and Jinming Zhou

Bioorganic Chemistry, 2024, 149, 107466
DOI: 10.1016/j.bioorg.2024.107466

EROS protein: Decoding its pivotal role in redox homeostasis and disease pathogenesis

Shiyu Liang, Youli Zhou, Wenfeng Ren, Yang Xu, Ming Tang, Yuxi Su, Li Li and Mei Gao

Advances in Redox Research, 2026, 18, 100147
DOI: 10.1016/j.arres.2025.100147

USP13: A therapeutic target for combating tumorigenesis and antitumor therapy resistance

Lina Yi, Akezhouli Shahatiaili, Lin Zhang, Haihua He, Leifeng Chen, Zhen Zhang, Fushan Gao, Fei Shao, Yibo Gao and Jie He

International Journal of Biological Macromolecules, 2025, 304, 140608
DOI: 10.1016/j.ijbiomac.2025.140608

Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives

Jiao Li, Zhenyu Cai, Xu-Wen Li and Chunlin Zhuang

J. Med. Chem., 2022, 65, 13533
DOI: 10.1021/acs.jmedchem.2c01223

Tumor microenvironment responsive nano-PROTAC for BRD4 degradation enhanced cancer photo-immunotherapy

Zheng Li, Guodong Ren, Xuewei Wang, Xiaowan Li, Lingwen Ding, Jianwei Zhu, Yajie Zhang, Chengwu Zhang, Jianhua Zou and Xiaoyuan Chen

Biomaterials, 2025, 322, 123387
DOI: 10.1016/j.biomaterials.2025.123387

Enzyme‐Activated Orthogonal Proteolysis Chimeras for Tumor Microenvironment‐Responsive Immunomodulation

Caixia Sun, Songhan Liu, Jun Wei Lau, Hanyu Yang, Yun Chen and Bengang Xing

Angewandte Chemie, 2025, 137
DOI: 10.1002/ange.202423057

Covalent Bifunctional Molecules (CBMs): Achievements and Challenges

Yuting Xin, Fangsu Chen, Qidong You, Lei Wang and Qiuyue Zhang

Medicinal Research Reviews, 2026, 46, 176
DOI: 10.1002/med.70011

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety

Renshuai Zhang, Songbo Xie, Jie Ran and Te Li

Journal Cellular Physiology, 2024, 239
DOI: 10.1002/jcp.31255

Repurposing AS1411 for constructing ANM-PROTACs

Xuekun Fu, Jin Li, Xinxin Chen, Hongzhen Chen, Zhuqian Wang, Fang Qiu, Duoli Xie, Jie Huang, Siran Yue, Chunhao Cao, Yiying Liang, Aiping Lu and Chao Liang

Cell Chemical Biology, 2024, 31, 1290
DOI: 10.1016/j.chembiol.2024.03.011

Rational Proteolysis Targeting Chimera Design Driven by Molecular Modeling and Machine Learning

Shuoyan Tan, Zhenglu Chen, Ruiqiang Lu, Huanxiang Liu and Xiaojun Yao

WIREs Comput Mol Sci, 2025, 15
DOI: 10.1002/wcms.70013

Design of RGD-functionalized GSH-responsive pegylated polymeric protacs for selective BRD4 degradation and EndMT-driven cardiac fibrosis inhibition

Tao Bi, Lei Chen, Ting Wang, Wenjun Miao, Silong Zhai, Rui Huang, Qin Sun, Yihan Chen, Hongna Su, Jie Zhou, Ruowen Li, Weixue Huang, Xiaojun Yao, Pei Luo and Zengjin Liu

J Nanobiotechnol, 2026, 24
DOI: 10.1186/s12951-026-04036-7

Stapled peptide PROTAC induced significantly greater anti-PD-L1 effects than inhibitor in human cervical cancer cells

Yu-Ying Shi, An-Jin Wang, Xue-Lian Liu, Meng-Yuan Dai and Hong-Bing Cai

Front. Immunol., 2023, 14
DOI: 10.3389/fimmu.2023.1193222

ELiAH: the atlas of E3 ligases in human tissues for targeted protein degradation with reduced off-target effect

Hyojung Paik, Chunryong Oh, Sajid Hussain, Sangjae Seo, Soon Woo Park, Tae Lyun Ko and Ari Lee

Database, 2024, 2024
DOI: 10.1093/database/baae111

Overcoming cancer therapy resistance: From drug innovation to therapeutics

Jin-Rui Wei, Meng-Yi Lu, Tian-Hua Wei, Joshua S. Fleishman, Hui Yu, Xiao-Li Chen, Xiang-Tu Kong, Shan-Liang Sun, Nian-Guang Li, Ye Yang and Hai-Wen Ni

Drug Resistance Updates, 2025, 81, 101229
DOI: 10.1016/j.drup.2025.101229

Discovering Uncharted Binding Pockets on E3 Ligases Leads to the Identification of FBW7 Allosteric Modulators

Míriam Martínez‐Cartró, Álvaro Serrano‐Morrás, Andrea Bertran‐Mostazo, Roger Castaño‐Muñiz, Salvatore Scaffidi, Varbina Ivanova, Noémi Csorba, József Simon, Péter Ábrányi‐Balogh, Yunfeng Li, György M. Keserü, Bing Hao, Xavier Barril and Carles Galdeano

Advanced Science, 2025, 12
DOI: 10.1002/advs.202506068

Development of folate receptor targeting chimeras for cancer selective degradation of extracellular proteins

Yaxian Zhou, Chunrong Li, Xuankun Chen, Yuan Zhao, Yaxian Liao, Penghsuan Huang, Wenxin Wu, Nicholas S. Nieto, Lingjun Li and Weiping Tang

Nat Commun, 2024, 15
DOI: 10.1038/s41467-024-52685-9

Workflow for E3 Ligase Ligand Validation for PROTAC Development

Nebojša Miletić, Janik Weckesser, Thorsten Mosler, Rajeshwari Rathore, Marina E. Hoffmann, Paul Gehrtz, Sarah Schlesiger, Ingo V. Hartung, Nicola Berner, Stephanie Wilhelm, Juliane Müller, Bikash Adhikari, Václav Němec, Saran Aswathaman Sivashanmugam, Lewis Elson, Hanna Holzmann, Martin P. Schwalm, Lasse Hoffmann, Kamal Rayees Abdul Azeez, Susanne Müller, Bernhard Kuster, Elmar Wolf, Ivan Đikić and Stefan Knapp

ACS Chem. Biol., 2025, 20, 507
DOI: 10.1021/acschembio.4c00812

Stimuli-activatable protein degraders for targeted cancer therapy: from prodrug design to nanoplatform applications

Xingyu Jiang, Yinuo Chen, Yunna Gao, Rui Rong, Yi Lai, Zheying Zhu and Zhiai Xu

Advanced Drug Delivery Reviews, 2026, 232, 115808
DOI: 10.1016/j.addr.2026.115808

Self‐Oxygenating PROTAC Microneedle for Spatiotemporally‐Confined Protein Degradation and Enhanced Glioblastoma Therapy

Xingyu Jiang, Yi Lai, Wenzheng Xia, Wenfang Yang, Junjue Wang, Jiaxing Pan, Qian Zhao, Feng Zhou, Shiqin Li, Shunan Zhang, Jing Gao, Yinyan Wang, Tao Zan, Zhi Ping Xu, Haijun Yu and Zhiai Xu

Advanced Materials, 2025, 37
DOI: 10.1002/adma.202411869

The progress of molecules and strategies for the treatment of HBV infection

Youlu Pan, Heye Xia, Yanwen He, Shenxin Zeng, Zhengrong Shen and Wenhai Huang

Front. Cell. Infect. Microbiol., 2023, 13
DOI: 10.3389/fcimb.2023.1128807

Synthesis of selective BCL-XL PROTAC and potent antitumor activity in glioblastoma

Meichen Liu, Biao Sun, Rui Niu, Yue Zhang, Xinyu Li, Jiefei Wang, Xin Wang and Jinlong Yin

Cell Reports Physical Science, 2025, 6, 102593
DOI: 10.1016/j.xcrp.2025.102593

Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design

Dazhao Mi, Yuzhan Li, Haijun Gu, Yan Li and Yihua Chen

European Journal of Medicinal Chemistry, 2023, 256, 115444
DOI: 10.1016/j.ejmech.2023.115444

Click-constructed modular signal aptamer chimeras enable receptor-independent degradation of membrane proteins

Wanlin Xie, Weidi Sun, Qin Li, Yang Dang, Lele Ma, Yuan Liu, Hui Zhang, Fengli Qu and Weihong Tan

Proc. Natl. Acad. Sci. U.S.A., 2025, 122
DOI: 10.1073/pnas.2424500122

NanoTAC in targeted protein degradation: Intelligent delivery platforms and synergistic therapeutic paradigms

Jieying Qian, Hongtao Duan, Qingqi Zheng, Yuzhao Yang, Xiaowan Huang, Bingyang Shi and Yunjiao Zhang

Advanced Drug Delivery Reviews, 2026, 232, 115821
DOI: 10.1016/j.addr.2026.115821

Targeting BRD4 in cancer therapy: From inhibitors and degraders to novel combination strategies and resistance mechanisms

Xi-Bo Wang, Rui-Jing Meng, Wen-Jin Cao, Lei Cheng, Junmin Zhang and Shi-Wu Chen

Bioorganic & Medicinal Chemistry, 2026, 132, 118473
DOI: 10.1016/j.bmc.2025.118473

Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders

Panrui Lu, Yalong Cheng, Lei Xue, Xintong Ren, Xilong Xu, Chenglong Chen, Longzhi Cao, Jiaojiao Li, Qingcui Wu, Shan Sun, Junjie Hou, Wei Jia, Wei Wang, Yan Ma, Zhaodi Jiang, Chao Li, Xiangbing Qi, Niu Huang and Ting Han

Cell, 2024, 187, 7126
DOI: 10.1016/j.cell.2024.10.015

A Multi-Split-and-Mix Platform for a Variety of Targeted Protein Degradation

Yuechen Wang, Qinhong Luo, Yun Xing, Rui Wang, Fenfang Yang, Weifan Cao, Zigang Li and Feng Yin

ACS Chem. Biol., 2025, 20, 2287
DOI: 10.1021/acschembio.5c00444

MAGL targeted PROTAC degrader simultaneously enhances P53 for synergistic treatment of glioblastoma stem cell

Zheng Yuan, Meixia Guo, Yue Zhang, Yilin Deng, Biao Sun, Yaning Hou, Xin Wang, Xiong Jin, Yang Liu, Bingyang Shi and Jinlong Yin

Cell Death Discov., 2025, 11
DOI: 10.1038/s41420-025-02392-1

Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives

Jiarui Hu, Dan Zhang, Keyue Tian, Changyu Ren, Heng Li, Congcong Lin, Xiaoli Huang, Jie Liu, Wuyu Mao and Jifa Zhang

European Journal of Medicinal Chemistry, 2023, 256, 115475
DOI: 10.1016/j.ejmech.2023.115475

Insight into Structure-Activity Relationship of New Compounds for Breast Cancer Treatment

Lu Li and Qiangsheng Zhang

CTMC, 2023, 23, 2373
DOI: 10.2174/0115680266253686230921054429

Homo-BacPROTAC-induced degradation of ClpC1 as a strategy against drug-resistant mycobacteria

Lukas Junk, Volker M. Schmiedel, Somraj Guha, Katharina Fischel, Peter Greb, Kristin Vill, Violetta Krisilia, Lasse van Geelen, Klaus Rumpel, Parvinder Kaur, Ramya V. Krishnamurthy, Shridhar Narayanan, Radha Krishan Shandil, Mayas Singh, Christiane Kofink, Andreas Mantoulidis, Philipp Biber, Gerhard Gmaschitz, Uli Kazmaier, Anton Meinhart, Julia Leodolter, David Hoi, Sabryna Junker, Francesca Ester Morreale, Tim Clausen, Rainer Kalscheuer, Harald Weinstabl and Guido Boehmelt

Nat Commun, 2024, 15
DOI: 10.1038/s41467-024-46218-7

PCSK9 Promotes Atherosclerotic Plaque Instability by Inducing VSMC Ferroptosis through the YAP1–NUPR1 Axis

Yuting Cui, Yanyu Chen, HengJuan Li, Weizheng Zhang, Xin Wang, Mengdie Xia, Ni Gan, Yating Zhou, Man Li, Huayu Zhang, Qiong Xiang, Xi-Long Zheng, Gang Fan, Jing Yang, Juan Peng, Xiaoyan Dai and Zhihan Tang

Research, 2025, 8
DOI: 10.34133/research.0922

FGFs/FGFRs and neuroinflammatory diseases: mechanism, drug therapies and delivery systems

Juan Wang, Lijuan Xing, Yang Song, Yue Yang, Yinzhuo Zhang, Haoxiang Ma, Benyu Su, Luoxuan Su, Chao Ma, Mingyan Liu and Ke Du

Journal of Advanced Research, 2025, 78, 733
DOI: 10.1016/j.jare.2025.06.024

Proteolysis Targeting Chimeras (PROTACs) based on celastrol induce multiple protein degradation for triple-negative breast cancer treatment

Xuelan Gan, Fan Wang, Jianguo Luo, Yunfei Zhao, Yan Wang, Chao Yu and Jun Chen

European Journal of Pharmaceutical Sciences, 2024, 192, 106624
DOI: 10.1016/j.ejps.2023.106624

Targeted Protein Degradation for Agricultural Applications: Rationale, Challenges, and Outlook

Denis Fourches, Joseph Pilotte, Brian E. Watts, Daniel J. Saltzberg and Robert M. Cicchillo

ACS Bio Med Chem Au, 2025, 5, 778
DOI: 10.1021/acsbiomedchemau.5c00111

Boosting bioavailability of PROTACs for ovarian cancer: From chemistry to clinical translation

Mokhtar Rejili, Md Sadique Hussain, Faouzi Haouala, Yumna Khan, Mudasir Maqbool and Gaurav Gupta

Bioorganic Chemistry, 2025, 166, 109097
DOI: 10.1016/j.bioorg.2025.109097

Functionalized Photoimmune Hydrogel Microspheres for Inside‐Out Eradication of Osteosarcoma via a PD‐L1 PROTAC Strategy

Huanhuan Luo, Jun Ma, Haiyang Yang, Haodong Hu, Zhuoming Xu, Lingli Jin, Jiayi Chen, Chenhong Qian, Jingyi Ju, Yongqing Zhang, Li Zheng, Kang Ji, Yi Li and Gang Chen

Adv Healthcare Materials, 2026, 15
DOI: 10.1002/adhm.202503988

The rise of new targets in melanoma

Xue Bai and Keith T Flaherty

British Journal of Dermatology, 2025, 193, 1056
DOI: 10.1093/bjd/ljaf251

Targeting glycolytic enzymes to combat cancer metastasis: Strategies toward clinical translation

Dan Zhang, Yujia He and Yu He

Biochemical Pharmacology, 2026, 243, 117499
DOI: 10.1016/j.bcp.2025.117499

Emerging magic bullet: subcellular organelle-targeted cancer therapy

Yue Yan, Yimeng Zhang, Jianxiong Liu, Binlong Chen and Yiguang Wang

Medical Review, 2025, 5, 117
DOI: 10.1515/mr-2024-0044

Characteristic roadmap of linker governs the rational design of PROTACs

Yawen Dong, Tingting Ma, Ting Xu, Zhangyan Feng, Yonggui Li, Lingling Song, Xiaojun Yao, Charles R. Ashby and Ge-Fei Hao

Acta Pharmaceutica Sinica B, 2024, 14, 4266
DOI: 10.1016/j.apsb.2024.04.007

Current strategies for senescence treatment: Focused on theranostic performance of nanomaterials

Yiyang Cong, Xiaoyang Li and Hao Hong

Journal of Controlled Release, 2025, 382, 113710
DOI: 10.1016/j.jconrel.2025.113710

Discovery of a selective CDK7 PROTAC against acute leukemia with low platelet toxicity

Yutong Tu, Xiaojia Cai, Zhaofan Tao, Ruisen Zhang, Xian Li, Beijing Chen, Hualin Zhang, Xiaobei Hu, Jiayi Ke, Xiaoya Chen, Xinyan Bai, Jia Li, Tianfeng Xu and Yubo Zhou

Leukemia, 2026
DOI: 10.1038/s41375-026-02925-2

PROTAC-mediated FTO protein degradation effectively alleviates diet-induced obesity and hepatic steatosis

Yang Xiao, Tianyu Jiang, Xinyi Qi, Jinfeng Zhou, Tingli Pan, Qichao Liao, Siqi Liu, Hao Zhang, Jiale Wang, Xinzhen Yang, Lin Yu, Yuehui Liang, Xue Liang, Batbold Batsaikhan, Turtushikh Damba, Khongorzul Batchuluun, Yunxiao Liang, Ying Zhang, Yixing Li and Lei Zhou

International Journal of Biological Macromolecules, 2025, 285, 138292
DOI: 10.1016/j.ijbiomac.2024.138292

A Dual-Targeted Molecule for Disease-Activatable Proteolysis Targeting Chimeras and Targeted Radionuclide Therapy of Cancer

Yuan Zhang, Wei Gu, Wan Chen, Jieli Zhu, Longfei Fan, Liwen Zhang, Liangyou Zhao and Qingqing Miao

J. Am. Chem. Soc., 2025, 147, 7897
DOI: 10.1021/jacs.4c18398

The Potential of Proteolysis-Targeting Chimeras for Weed Control

Ramon G. Leon

outlook pest man, 2024, 35, 18
DOI: 10.1564/v35_feb_04

A Physiologically Responsive Nanocomposite Hydrogel for Treatment of Head and Neck Squamous Cell Carcinoma via Proteolysis‐Targeting Chimeras Enhanced Immunotherapy

Yaping Wu, Xiaowei Chang, Guizhu Yang, Li Chen, Qi Wu, Jiamin Gao, Ran Tian, Wenyun Mu, John Justin Gooding, Xin Chen and Shuyang Sun

Advanced Materials, 2023, 35
DOI: 10.1002/adma.202210787

TRAP1 drives smooth muscle cell senescence and promotes atherosclerosis via HDAC3-primed histone H4 lysine 12 lactylation

Xuesong Li, Minghong Chen, Xiang Chen, Xian He, Xinyu Li, Huiyuan Wei, Yongkang Tan, Jiao Min, Tayyiba Azam, Mengdie Xue, Yunjia Zhang, Mengdie Dong, Quanwen Yin, Longbin Zheng, Hong Jiang, Da Huo, Xin Wang, Shaoliang Chen, Yong Ji and Hongshan Chen

European Heart Journal, 2024, 45, 4219
DOI: 10.1093/eurheartj/ehae379

The rise of degrader drugs

Mingxing Teng and Nathanael S. Gray

Cell Chemical Biology, 2023, 30, 864
DOI: 10.1016/j.chembiol.2023.06.020

A Self-Assembled Nano-Molecular Glue (Nano-mGlu) Enables GSH/H2O2-Triggered Targeted Protein Degradation in Cancer Therapy

Jie Sun, Mingxi Gu, Lvyang Peng, Jing Guo, Peng Chen, Yalei Wen, Fang Feng, Xiaojuan Chen, Tongzheng Liu, Yongheng Chen, Xiaoyun Lu, Liqian Gao, Shao Q. Yao and Peiyan Yuan

J. Am. Chem. Soc., 2025, 147, 372
DOI: 10.1021/jacs.4c11003

Self-Assembled Nano-PROTAC Enables Near-Infrared Photodynamic Proteolysis for Cancer Therapy

Weishan Wang, Chenghong Zhu, Bin Zhang, Yi Feng, Yan Zhang and Jinbo Li

J. Am. Chem. Soc., 2023, 145, 16642
DOI: 10.1021/jacs.3c04109

Targeted protein degradation in autoimmune diseases: from mechanisms to therapeutic breakthroughs

Yuxin Song, Boyang Zhou, Jiangang Long and Yunhua Peng

Journal of Autoimmunity, 2025, 156, 103475
DOI: 10.1016/j.jaut.2025.103475

Site-resolved assessment of targeted protein degradation

Ricardo Moreno-Ballesteros, Thomas Pembridge, Gaurav Beniwal and Satpal Virdee

Cell Chemical Biology, 2025, 32, 969
DOI: 10.1016/j.chembiol.2025.06.002

Next‐Generation Proteolysis‐Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation

Mohamed S. Nafie, Mohamed K. Diab, Asmaa S. A. Yassen, Amany M. Elshamy, Mohamed R. El Tohamy, Haytham O. Tawfik and Sherif Ashraf Fahmy

Drug Development Research, 2025, 86
DOI: 10.1002/ddr.70192

Identification of a Potent and Selective CDK9 Degrader as a Targeted Therapeutic Option for the Treatment of Small-Cell Lung Cancer

Yubo Wang, Mengmeng Wang, Lan Ma, Yan Zhang, Yue Jiao, Shuxin Zhang, Yijie Yang, Jialu Li, Mingming Wei, Sheng Cao, Kun Zhang, Shuangwei Liu and Guang Yang

J. Med. Chem., 2025, 68, 2528
DOI: 10.1021/acs.jmedchem.4c01621

SAG/RBX2/ROC2/RNF7 dual E3 ligase: From target identification, validation to drug discovery

Qing Yu, Shizhen Zhang, Zhijian Li, Ting Liang and Yi Sun

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026, 1881, 189546
DOI: 10.1016/j.bbcan.2026.189546

Overview of PRMT1 modulators: Inhibitors and degraders

Junwei Wu, Deping Li and Lifang Wang

European Journal of Medicinal Chemistry, 2024, 279, 116887
DOI: 10.1016/j.ejmech.2024.116887

Dual-Action-Only PROTACs

Ranit Dutta, Anirudh Devarajan, Amelia Talluri, Ritam Das and S. Thayumanavan

J. Am. Chem. Soc., 2025, 147, 9074
DOI: 10.1021/jacs.5c00131

HerTACs Enable Tumor‐Selective Lysosomal Degradation of Membrane and Extracellular Proteins via HER2 Trafficking

Shipeng He, Wenjing Huang, Yaojin Zhu, Fei Gao, Yuxin Fang, Jiayi Zhu, Yuhan Bao, Guoqiang Dong and Chunquan Sheng

Angew Chem Int Ed, 2025, 64
DOI: 10.1002/anie.202511467

Development of natural product-based targeted protein degraders as anticancer agents

Cheng Chen, Yanyan Feng, Chen Zhou, Zhouyan Liu, Ziwei Tang, Ye Zhang, Tong Li, Chenglei Gu and Jichao Chen

Bioorganic Chemistry, 2024, 153, 107772
DOI: 10.1016/j.bioorg.2024.107772

Emerging pharmacology of targeted protein degraders

Samir H. Barghout and Mohamed A. Eldeeb

The Journal of Pharmacology and Experimental Therapeutics, 2025, 392, 103694
DOI: 10.1016/j.jpet.2025.103694

PROTAC for agriculture: learning from human medicine to generate new biotechnological weed control solutions

Ramon G. Leon and Diane C. Bassham

Pest Management Science, 2024, 80, 262
DOI: 10.1002/ps.7741

Key Considerations in Targeted Protein Degradation Drug Discovery and Development

Liena Qin, Han Dai and Junfeng Wang

Front. Chem., 2022, 10
DOI: 10.3389/fchem.2022.934337

Self-assembled Nano-PROTACs: bridging chemical design and biological barriers in targeted protein degradation

Ni-Yuan Zhang, Jian-Xiao Liang, Bei-Ning Hu, Yi Wang, Hong-Wei An and Hao Wang

Advanced Drug Delivery Reviews, 2026, 234, 115861
DOI: 10.1016/j.addr.2026.115861

PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer

Hongyan Zhang, Longlong Zhang, Yuna He, Dewei Jiang, Jian Sun, Qianmei Luo, Huichun Liang, Tiantian Wang, Fubing Li, Yu Tang, Zimo Yang, Wenjing Liu, Yu Rao and Ceshi Chen

Cancer Letters, 2024, 598, 217112
DOI: 10.1016/j.canlet.2024.217112

Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment

Lianlian Fan, Weifang Tong, Anhui Wei and Xupeng Mu

International Journal of Biological Macromolecules, 2024, 275, 133680
DOI: 10.1016/j.ijbiomac.2024.133680

Design of conditional and tumor-activated PROTACs for selective degradation in lung cancer

Lin Lin, Fushuang Zheng, Hongyi Wei, Xiaojie Wu, Hengyi Yan and Yuanyuan Ding

European Journal of Medicinal Chemistry, 2026, 303, 118432
DOI: 10.1016/j.ejmech.2025.118432

Enzyme‐Activated Orthogonal Proteolysis Chimeras for Tumor Microenvironment‐Responsive Immunomodulation

Caixia Sun, Songhan Liu, Jun Wei Lau, Hanyu Yang, Yun Chen and Bengang Xing

Angew Chem Int Ed, 2025, 64
DOI: 10.1002/anie.202423057

Proteolysis-targeting chimera (PROTAC) nanomedicines toward cancer treatment: From synthesis to therapeutic delivery

Yilin Liu, Xiao Zhang, Xiaoyuan Chen and Fuwu Zhang

Biomaterials, 2026, 325, 123621
DOI: 10.1016/j.biomaterials.2025.123621